BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the quarter ended June 30, 2022.

BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced that 14 companies have been selected to participate in its annual program.

Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox.

Clairvoyant Therapeutics, a Canadian biotech company, is pleased to announce it has initiated the first of 15 planned sites for CLARITY, the company’s Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder (AUD) (formerly called alcoholism).

Pressure BioSciences, Inc. today announced the Company’s participation in the July 6th Emerging Growth Investor Conference.

RaySearch Laboratories AB (publ) announces that Harris Health System in Texas, USA , has placed an order for the treatment planning system RayStation®* for its Smith Clinic location.

Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/387,864, titled “3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Wendy Chang to Senior Vice President, Human Resources and Banmeet Anand, Ph.D., to Senior Vice President, Translational Medicine.

Pyramid Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PBI-200, a next-generation, highly brain penetrant inhibitor of the neurotrophic tyrosine receptor kinase (NTRK) currently in clinical development for the treatment of NTRK fusion-positive solid tumors.

Mylab Discovery Solutions, India’s leading biotechnology company, and Portland, OR-based Hemex Health, a medical diagnostic device company focused on creating diagnostics to transform frontline healthcare, announced the official launch of the Gazelle™ PathoCatch™ COVID-19 FIA test, their collaborative diagnostic solution for point-of-care (POC) testing in India.